Warfarin can safely be held for the short term
Can warfarin therapy be withheld safely for a short time in patients undergoing elective procedures?
Current guidelines from several European and US cardiology groups allow for the cessation of warfarin for up to 1 week in patients at risk for bleeding because of an invasive procedure such as dental surgery or colonoscopy. Although we still need more research to provide a definitive answer, this study does not refute these recommendations, finding that 0.59% of patients who stop treatment develop a thromboembolism within the subsequent 30 days. (LOE = 2b)
Garcia DA, Regan S, Henault L, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168(1):63-69. [PMID:18195197]
Warfarin treatment sometimes must be interrupted in patients undergoing surgery or dental procedures. The researchers conducted a large observational study to determine the impact of short-term warfarin discontinuation on the likelihood of developing a thromboembolic event over the subsequent 30 days. To assemble the data, the researchers contacted community-based physicians in 101 offices who were using a computer-based warfarin medical record (CoumaCare) and asked them to participate. These physicians treated patients as they normally would, stopping warfarin treatment (91.6%) or stopping but using a bridging therapy (8.4%) for elective procedures such as colonoscopy, dental work, or ophthalmic surgery. They excluded patients who were hospitalized for a procedure, since they couldn't track whether a bridging treatment was used. More than half the patients were receiving warfarin because of atrial fibrillation and 15.5% were receiving warfarin following a prosthetic valve replacement (29% of the latter group received heparin as bridging therapy). In 1293 interruptions of warfarin treatment in 1024 patients, 7 patients -- all in the no treatment cohort -- developed a clinically apparent thromboembolic event. This prevalence translates into a rate of 0.54%. Most of the patients in the withheld warfarin group had treatment stopped for 5 days or fewer. Two of the 7 patients were at high risk of thrombosis because of a recent history of thromboembolism or active malignancy. The low number of thromboembolic events, though good for patients in the study, limits our confidence in these data, and a larger study is needed. That being said, it is reassuring that most patients who stop taking warfarin for 5 or fewer days are at little risk of an thromboembolic event.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.